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Abstract: Monosomy of chromosome 17 may affect the assessment of HER2 amplification. Notably, the prevalence 
ranges from 1% up to 49% due to lack of consensus in recognition. We sought to investigate the impact of mono-
somy of chromosome 17 to interpretation of HER2 gene status. 201 breast carcinoma were reviewed for HER2 gene 
amplification and chromosome 17 status. FISH analysis was performed by using double probes (LSI/CEP). Absolute 
gene copy number was also scored per each probe. HER2 FISH test was repeated on serial tissue sections, ranging 
in thickness from 3 to 20 µm. Ratio was scored and subsequently corrected by monosomy after gold control test 
using the aCGH method to overcome false interpretation due to artefactual nuclear truncation. HER2 immunotests 
was performed on all cases. 26/201 cases were amplified (13%). Single signals per CEP17 were revealed in 7/201 
(3.5%) cases. Five out of 7 cases appeared monosomic with aCGH (overall, 5/201, 2.5%) and evidenced single 
signals in >60% of nuclei after second-look on FISH when matching both techniques. Among 5, one case showed 
amplification with a pattern 7/1 (HER2/CEP17>2) of copies (3+ at immunotest); three cases revealed single signals 
per both probes (LSI/CEP=1) and one case revealed a 3:1 ratio; all last 4 cases showed 0/1+ immunoscore. We 
concluded that: 1) monosomy of chromosome 17 may be observed in 2.5% of breast carcinoma; 2) monosomy of 
chromosome 17 due to biological reasons rather than nuclear truncation was observed when using the cut-off of 
60% of nuclei harboring single signals; 3) the skewing of the ratio due to single centromeric 17 probe may lead to 
false positive evaluation; 4) breast carcinomas showing a 3:1 ratio (HER2/CEP17) usually show negative 0/1+ im-
munoscore and <6 gene copy number at FISH.
Keywords: Breast carcinoma, monosomy, chromosome 17, HER 2 amplification, FISH analysis, double probes, 
aCGH method, single signals, ratio (HER2/CEP 17), false positive
Introduction
The presence of monosomy of chromosome 17 
among breast carcinoma has been already doc-
umented [1, 2]. Differently to the biological pat-
terns of gains and/or polysomies of chromo-
some 17 [3], the impact of monosomy of chro-
mosome 17 during the HER2 gene testing, has 
not been extensively studied [4]. At clinical 
level, the features of monosomy of chromo-
some 17 is still a matter of debate, with some 
arguing a worse prognostic value and less 
responsiveness to anti-HER2 targeted therapy 
[1]. The most recent guidelines (ASCO/CAP 
2013) addressed appropriate HER2 scoring 
among common and uncommon patterns of 
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HER2 values [5, 6] and about the monosomy of 
chromosome 17 it has been observed that this 
pattern may lead to overall false interpretation, 
caused by the skewing of the ratio due to single 
centromeric 17 probe loss [4]. Some reports 
also compared the presence of single signals 
due to the artefactual nuclear truncation ver-
sus those being as true biological pattern [7], 
however no consensus is actually achieved. 
The recognition of gains/polysomy of chromo-
some 17, was changed along time and the over-
all interpretation was gradually modified 
through consensus and guidelines [8, 9], differ-
ently from the recognition of monosomy of 
chromosome 17. We sought to evaluate the 
incidence and impact of monosomy of chromo-
some 17 to HER2 testing, focusing at technical 
level the analytical phase, to avoid misinterpre-




201 consecutive cases were recruited from the 
Database of the Fluorescent Molecular Lab 
Verona, Italy. Cases represented breast carci-
noma with matched immunophenotypical and 
molecular analysis for HER2. All cases were 
tested for HER2 by immunohistochemistry and 
by FISH technique (not only score 2+ cases). 
Immunophenotypical analysis
All cases were tested with the Hercept test 
(Dako Glostrup, Denmark) and scored accord-
ing to 2013 ASCO/CAP [5]. 
Molecular interphase cytogenetic FISH analy-
sis
Analysis was performed on formalin-fixed, par-
affin embedded tissues. Cytogenetic analysis 
was performed using commercially available 
locus-specific probes mapping the chromo-
some 17 centromere and HER2 hot locus 
(Abbott-Vysis, Milan). FISH procedure was 
developed according to standard protocol from 
the company. Five-micron sections were cut 
from paraffin-embedded blocks. The slides 
were examined using an Olympus BX61 
(Olympus, Hamburg, Germany) with appropri-
ate filters for Spectrum Orange, Spectrum 
Green and the UV filter for the DAPI nuclear 
counterstain. The signals were recorded with a 
CCD camera (CytoVysion, Olympus Berlin, 
Germany). 
Controls
To avoid false interpretation of single fluores-
cent signals due to nuclear truncation at serial 
sections of the paraffin blocks, we retested 
cases showing single signals for HER2 by using 
additional thickness ranging from 3 to 5, 10, 15 
and up to 20 µm per case. Monosomy of chro-
mosome 17 was assessed when at least 60% 
of nuclei harbored single fluorescent centro-
meric signals. Ratio was initially scored and 
subsequently corrected by monosomy. Again, 
HER2 immunotests (Hercept Test) were 
matched for all cases. 
Array comparative genomic hybridization 
(aCGH) analysis
Genomic DNA was isolated using QIAamp DNA 
mini kit (Qiagen, Valensia, CA, Usa) and quanti-
fied on the NanoDrop-1000 Spectrophotometer 
(NanoDrop Technologies Inc., DE, USA). The 
quantities and qualities of the DNA allowed us 
to continue with the analyses.  With Agilent 
Table 1. Histopathological and immunophe-
notypical features of 201 consecutive breast 
carcinomas
Breast cancers, n (%)
Histotype
    Ductal 159 (79.1)
    Lobular 31 (14.4)
    Special types 11 (5.5)
Grade
    G1 58 (28.9)
    G2 113 (56.2)
    G3 30 (14.9)
pT
    pT1 142 (70.6)
    pT2 49 (23.4)
    pT3 10 (5)
pN
    N+ 49 (24.4)
    N- 152 (75.6)
Molecular subtype
    Luminal A 96 (47.8)
    Luminal B 54 (26.9)
    HER2-enriched 23 (11.4)
    Triple negative 28 (13.9)
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Human 244K array format/platform containing 
around 244000 oligonucleotide probes, cover-
ing the coding and noncoding genome regions 
(Agilent Technologies, Santa Clara, CA), we test-
ed tumors for assessment of the genomic pro-
file, previously screened by FISH analysis. 
Briefly, 1.5 µg of tumor DNA and gender-
matched reference DNA were digested, labeled, 
hybridized and washed according to Agilent 
Oligonucleotide Array-Based CGH for Genomic 
DNA analysis protocol version 6.1 (Agilent 
Technologies, Santa Clara, CA, USA). The 
digested DNAs were labeled by random priming 
with Cy3-dUTP (reference DNA) and Cy5-dUTP 
(patient DNA) by use of the Agilent Complete 
SureTag Complete DNA Labeling Kit (Agilent 
Technologies, Santa Clara, CA, USA), after 
which the labeled DNAs were purified. The reso-
lution of the fragments analyzed varied from 
several Kb to 1 Mb depending upon the case 
selected. The array images obtained after scan-
ning (high resolution Agilent scanner) were pro-
cessed with the Feature Extraction software 
(v11.5.1.1.), and the output data files were ana-
lyzed with the Agilent CytoGenomics v.2.0.6.0 
Software. To identify copy number alterations 
we used Aberration Detection Method 2 (ADM-
2) algorithm with sensitivity threshold of 6.0. 
(and in our lab the default aberration filter with 
minimum number or probes in region is 3 and 
minimum absolute average log ratio of region is 
0.25) and to exclude the small variances in the 
data we set up a custom aberration filter identi-
fying an alterations in copy number if minimum 
of 8 probes gained or lost to be present and 
with minimum absolute average log ratio for 
region to be 0.5. The region with small copy 
number variations were excluded by comparing 
and visualizing the copy number variant regions 
tool of the CytoGenomics software.
Interpretation
We primarily scored the absolute numbers of 
HER2 spots and the centromeric ones. For the 
purpose of the actual study we initially catego-
rized a case as “amplified” when the presence 
of absolute number of HER2 set >6 and if the 
ratio (HER2/CEP17) set ≥2. We also catego-
rized the presence of single signals for chromo-
some 17 reporting the percentage and the 
interpretation of monosomic status of the chro-
mosome. We secondly matched the score of 
the analytical phase to interpretation of aCGH 
findings and corrected the false positive and 
negative interpretation. 
Digital imaging analysis
FISH slides were also digitalized by D-Sight/
Fluo instrument (Visia Imaging, Florence, Italy). 
FISH digital analysis was performed as addi-
tional control for scoring, due to the capacity of 
the instruments to assess hundred of nuclei.
Ethical issues
Our internal Institutional review board approved 
the design and aim of the actual study 
(07012015 request).
Results
Clinico-pathological and molecular findings are 
summarized in Tables 1 and 2.
Pathological findings
159/201 (79.1%) breast carcinomas showed 
ductal differentiation (Figure 1), 31/201 
(14.4%) lobular and the remaining minor sub-
types. 58/201 (28.9%) revealed G1, 113 
(56.2%) G2 and 30 (14.9%) G3 grading of dif-
Table 2. Breast carcinoma with monosomy of chromosome 17: relevant clinico-pathological and mo-
lecular characters
Case Age pT Molecular subtype
HER2 
IHC
FISH Nuclei with 
loss CEP17 (%)
HER2 status 
by FISH aCGH status on  chr. 17
Interpretation losses 
of CEP17
1 77 pT1 Luminal A 1 70 Not amplified Whole loss Monosomy
2 63 pT2 Triple negative 1 80 Not amplified Loss 17p and gain 17q Monosomy
3 38 pT1 Luminal A 0 70 Not amplified Loss part of chr 17q Monosomy
4 34 pT1 Triple negative 0 75 Not amplified Loss 17p and part of 17q Monosomy
5 53 pT1 (bilateral) Luminal B 3 80 Amplified Loss part of 17q Monosomy
6 42 pT1 Luminal A 0 30 Not amplified Flat Nuclear truncation
7 80 pT3 Triple negative 1 20 Not amplified Flat Nuclear truncation
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ferentiation. 142/201 (70.6%) staged pT1, 
49/201 (23.4%) pT2 and 10/201 (5%) pT3. 
Immunophenotypical findings
96/201 (47.8%) of breast carcinomas were 
Luminal A, 54/201 (26.9%) Luminal B, 23/201 
(11.4%) HER2-enriched and 28/201 (13.9%) 
triple negative (Figure 1).
FISH cytomolecular findings
26/201 cases were amplified (13%). Single sig-
nals per CEP17 were revealed in 7/201 (3.5%) 
cases. Five out of 7 cases (overall 2/201, 2.5%) 
appeared monosomic after matching with 
aCGH analysis and evidenced single signals in 
>60% of nuclei after second-look on FISH anal-
ysis (Figure 2; Table 2). Among 5, one case 
showed amplification with a pattern 7/1 (HER2/
CEP17>2) of copies (3+ at immunotest); three 
cases revealed single signals per both probes 
(LSI/CEP=1) and one case revealed a 3:1 (LSI/
CEP>2) count ratio; importantly all last 4 cases 
showed 0/1+ score at immunotest. All cases 
except one (6/7) exhibited <6 absolute HER2 
gene copy number. One case showed seven 
signals.
aCGH molecular findings
Two cases revealed complete loss of whole 
chromosome 17 (Figure 2). One case revealed 
a complete loss of chromosome 17q and part 
of chromosome 17p (Figure 3). One case evi-
denced a loss of chromosome 17q with a par-
tial gains of the telomeric chromosome 17p 
region. One case showed a complex chromo-
some rearrangement and imbalance on chro-
mosome 17 (possible loss of chromosome 17 
with the formation of an isochromosome for 
long arm of chromosome 17 and an unbal-
anced translocation with retention of the deriv-
ative chromosome containing 17q material and 
Figure 1. Breast carcinoma with monosomy of chromosome 17. Ductal phenotype, luminal A young age (2/5 cases 
<38 years) (A); triple negative breast carcinoma (2/5 cases) (B); a case of bilateral breast carcinoma (1/5) (C). Four 
out of five displayed a negative (0 or 1+) HER2 immunoscore (D).
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the HER2 locus). All these cases revealed >60% 
of neoplastic nuclei harboring single signals per 
CEP17 at FISH analysis (Table 2; Figure 4). Type 
1 chr17 monosomy reveals loss of whole chro-
mosome 17 whereas type 2 chr17 monosomy 
show partial losses of chromosome 17 (i.e. loss 
of 17q, CEP17 and part of 17p). Two cases 
revealed a flat profile with absence of chromo-
some 17 aberrations (Table 2). These cases 
revealed <60% nuclei harboring single signals. 
At Hercept test, three cases showed score 0, 
three cases showed score 1+, one case scored 
3+ (Figure 1). The case showing 3+ at immu-
notest showed a pattern 7/1 (HER2/CEP17>2) 
at FISH test. The remaining showed respective-
ly 1/1 in four cases and 3:1 in one case.
Discussion
In the present study we show that: 1) monoso-
my of chromosome 17 may be observed in 
2.5% of breast carcinomas; 2) monosomy due 
to biological reasons rather than nuclear trun-
cation is observed when the cut-off set to 60% 
of nuclei; 3) the skewing of the ratio due to sin-
gle centromeric 17 probe may lead to false 
positive evaluation of HER2 gene amplification; 
4) when dealing with cases showing a 3:1 ratio 
(HER2/CEP17) the interpretation should be 
“HER2 negative”, being Her-2 negative at immu-
nolevel and characterized by <6 Her-2/neu sig-
nals. It is well known that chromosome 17 in 
breast cancer shows very complex abnormali-
ties and aneusomy of chromosome 17 can lead 
to troublesome Her2 gene assessment in rou-
tine diagnostic practice [10]. It has been dem-
onstrated that chromosome 17 polysomy is 
rare, but few data on monosomy are present in 
the literature, especially when dealing with 
interphase nuclei assessable on formalin fixed 
paraffin embedded samples. In the actual 
study, we show an analytical phase for the 
assessment of monosomy of chromosome 17 
in a series of consecutive breast carcinomas. 
Figure 2. Breast carcinoma with monosomy of chromosome 17. The tumor harbors single signals in >60% of neo-
plastic nuclei per both LSI Her-2/neu and CEP17 loci at FISH analysis and reveals loss of whole chromosome 17 
(type 1 monosomy) after aCGH molecular profiling.  
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Based on our data, monosomy of chromosome 
17 may be observed in about 2.5% of breast 
carcinomas. Among the Literature few data are 
recruitable due to the fact that most previous 
researches focused on gene amplification, poli-
somy and/or heterogeneity. Moreover there are 
no strictly standard guidelines on how to assess 
monosomy of chromosome 17 in interphase 
nuclei. The recent ASCO/CAP 2013 guidelines 
pose attention to the identification of unusual 
HER2 genotypic abnormalities, like aneusomy 
of chromosome 17 (i.e monosomy), that affect 
HER2/CEP17 ratio in dual signal in situ hybrid-
ization assays. From cytogenetists it is known 
that the skewing of the ratio due to single cen-
tromeric 17 probe may bring to false positive 
evaluation of gene amplification. All cases with 
monosomy of chromosome 17 except one did 
not show HER2 immunoexpression. In the liter-
ature a subset of such a cases may harbor pit-
falls when the copy number of HER2 duplicate, 
showing a 3:1 ratio. These scenarios happen 
when i.e. uniparental disomy and polyploidy 
nuclei replicate or when breast carcinoma 
BRCA positive progresses. Definitions of aneu-
somy 17 differ with the threshold criteria for 
monosomy. Setting the thresholds is compli-
cated not only by genomic heterogeneity and 
proliferative activity of tumors, but also by the 
substantial nuclear truncation resulting from 
tissue sectioning. Pathologists and biologists 
routinely dealing with molecular tests such as 
HER2 FISH assay are well aware of the pres-
ence of nuclear truncation. We know that up to 
30% of cells may display monosomy due to 
artefactual reasons. To overcome this gap, we 
retested all seven cases by using different 
thickness of tissue sections ranging from 3 to 
5, 10, 15 and up to 20 µm. All 5 cases showing 
the entire or partial loss of the chromosome 17 
Figure 3. Breast carcinoma with partial monosomy of chromosome 17. The tumor harbors single signals per both 
LSI Her-2/neu and CEP17 probes in >60% of neoplastic nuclei and evidenced losses of chromosome 17p, CEP17 
and the partial chromosome 17q12-21 (type 2 monosomy).
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at aCGH analysis maintained the pattern of 
single signals in more than 1000 nuclei count-
ed per case. Moreover, the digitalization of the 
images permitted the count of thousands of 
nuclei in at least five spots of the neoplastic tis-
sue. The two cases not confirmed at aCGH 
analysis as having a potential monosomic sta-
tus, revealed at aCGH presence of single sig-
nals per chromosome 17 in no more than 45% 
of nuclei at 5 µm thickness tissue sections. 
Cases that were confirmed as monosomic at 
aCGH analysis harbored at least 60% of nuclei 
with single fluorescent orange signals on tissue 
section evaluation. Type 1 chr17 monosomy 
reveals loss of whole chromosome 17 whereas 
type 2 chr17 monosomy shows partial losses of 
chromosome 17 (i.e. loss of 17q, CEP17 and 
part of 17p). When considering the cut-off of 
60% at FISH test, the cases matched with 
those characterized by monosomy at aCGH 
analysis. The aCGH technique is not biased by 
nuclear truncation and may be considered as 
gold standard. Reinholtz et al. reported similar 
findings (cut-off of 60% of nuclei) when evaluat-
ing thresholds for the recognition of monoso-
mic cases (one centromeric 17 signals). The 
higher the threshold is set, the lower is the pos-
sibility to face artefactual monosomy due to 
nuclear truncation; Nakopoulou et al., Reinholz 
et al. and Jemenez et al. respectively set the 
cut-off at least 40% of neoplastic nuclei, to 
60%, up to 80% for the monosomic status [11, 
12]. Kouvaras et al. focused on nuclear trunca-
tion during breast carcinoma HER2 assess-
ment. The HER2/CEP 17 ratios were compared 
in routine (4 μm) vs. thicker (15 μm) tissue sec-
tions. HER2 and CEP 17 number of signals 
increased in thick sections; however, HER2/
Figure 4. Recommendations’ on Her-2/neu FISH testing when single signals is observed at FISH analysis; when 
monosomy of chromosome 17 is observed (>60% nuclei with single CEP17 probe), use the single absolute Her-2/
neu gene copy number (>6) when distinguishing a case of breast carcinoma with amplification versus not amplified. 
Type 1 chr17 monosomy reveals loss of whole chromosome 17 whereas type 2 chr17 monosomy show partial losses 
of chromosome 17 (i.e. loss of 17q, CEP17 and part of 17p).
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CEP 17 ratios were decreased [7]. They con-
cluded that at least a subset of the equivocal 
cases could represent an artefactual increase 
of the ratio related to nuclear truncation and 
loss of peripheral CEP 17 signals in routine sec-
tions. In our study we assessed the cut-off per-
centage of nuclei harboring single signals due 
to nuclear truncation (<60%) versus those 
being characterized by biological pattern of 
monosomy of chromosome 17 (>60%). Gunn et 
al. matched aCGH and FISH analysis on 20 for-
malin fixed paraffin embedded tissue samples 
from newly diagnosed cases of invasive ductal 
carcinoma referred to their laboratory with 
unresolved HER2 status and revealed two false 
positives and one false negative by FISH due to 
“ratio skewing” caused by chromosomal gains 
and losses in the centromeric region [13]. 
Marchiò et al. elegantly evidenced the pres-
ence of part of chromosome 17 such as the 
single centromeric region to be gained in appar-
ent polysomic cases. The use of aCGH is useful 
in this contex of aneusomy of chromosome 17. 
In our cohort of cases the gold standard aCGH 
revealed in 4 cases the complete loss of the 
entire chromosome 17 (p and q arms and the 
centromeric region) and in one case a partial 
loss of two regions on the opposite arms. 
Reported incidences ranged from 0% to 49% 
for monosomy [2]. Some Authors reported the 
presence of cases having monosomy of chro-
mosome 17 when a mean of one single molec-
ular signal was assessed per nuclei [14, 15]. 
Other Authors performed the assessment of 
fine needle aspiration or touch preparation and 
interpreted the monosomic status not only 
when dealing with one signals per chromosome 
17 per nuclei but also when no signals were 
observed [12, 16-20]; a similar interpretation 
was scored on formalin-fixed and paraffin 
embedded tissues [11, 21]. A modulation of the 
score to assess the monosomic status of chro-
mosome 17 ranged from 1.23 to 1.75 [22-26]. 
Salido et al. reported the incidence of 2% of 
monosomy without specification of the cut-off 
[27]. Kokate et al. evaluated monosomy 17 and 
found a 7.3% incidence and was more prepon-
derant in FISH negative cases [28]. Our findings 
are also important for quality scheme of HER2 
assessment and external quality control. Most 
of these cases are considered negative by 
using a single probe approach (i.e <6 absolute 
copy number in 6/7 cases from the actual 
study) and do show 0 and or 1+ at immunohis-
tochemistry. Taking into account the ratio score 
by dual color ISH, the two cases showing ana-
lytically ratio >2 (3:1 LSI/CEP17 pattern) do not 
match with interpretation by using a single 
probe approach (three signals are <6). These 
contradictory findings are not due to pre-analyt-
ical problematic and agreement for interpreta-
tion is needed. At clinical level, preliminary find-
ings suggest that patients with metastatic 
breast cancer with HER2 amplification and 
chromosome 17 monosomy did not respond to 
trastuzumab [1]. Monosomy 17 also has been 
associated with nodal metastasis [11]. Results 
from N9831 further suggest that patients with 
primary breast cancer with HER2/CEP17 ratios 
greater than 15, most of whom displayed 
monosomy 17, did not benefit from adjuvant 
trastuzumab (hazard ratio 1.01) [29]. Inter- 
estingly, breast carcinoma with monosomy of 
chromosome 17 from our study, respectively 
showed a ductal phenotype, luminal A with 
young age in 2 out of 5 cases (<38 years), a 
triple negative phenotype in 2/5 cases and one 
case the patient was affected bilaterally by can-
cer. HER2 gene final interpretation is the results 
of a strong analytical phase. The analytical 
phase proposed from our study in such a cases 
is as follows: firstly, number the absolute copy 
number of HER2 and the centromeric color 
probes; secondly, assess the cases having the 
monosomic status if the centromeric probe 
show single signals in major than 60% of neo-
plastic nuclei (biological pattern rather than 
nuclear artefactual truncation); thirdly, the 
overall interpretation has to be posed to the 
absolute copy number of HER2 gene (>6 HER2 
gene amplification versus <6 HER2 not ampli-
fied). The subset 3:1 HER2/CEP17 patterns 
does merit a distinct evaluation at clinical level 
in order to test its predictiveness to the efficacy 
of actual targeted therapies already available 
or available in the near future.  Breast carcino-
mas showing a 3:1 ratio (HER2/CEP17) usually 
show negative 0 or 1+ immunoscore and <6 
overall gene copy number at FISH analysis by 
single probe approach.
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